Treatment results in all patients and according to risk group
| Result . | All patients, No. (%) (total n = 2178) . | Risk group, no. (%) of patients . | ||
|---|---|---|---|---|
| SRG (n = 636) . | MRG (n = 1299) . | HRG (n = 243) . | ||
| Death before remission3-150 | 22 (1.0) | 2 | 17 | 3 |
| Resistant disease | 16 (0.7) | 0 | 0 | 163-151 |
| CR achieved | 2140 (98.3) | 634 (99.7) | 1282 (98.7) | 224 (92.2) |
| Died in CR1 | 34 (1.6) | 5 | 16 | 13 |
| Relapses | ||||
| All | 385 (17.7) | 75 (11.8) | 184 (14.2) | 126 (51.9) |
| BM | 259 (11.9) | 44 (6.9) | 120 (9.2) | 95 (39.1) |
| CNS | 22 (1.0) | 7 (1.1) | 11 (0.8) | 4 (1.6) |
| Testes | 17 (0.8) | 3 (0.9) | 11 (1.5) | 3 (1.2) |
| Other isolated relapse | 5 (0.2) | — | 4 (0.4) | 1 (0.4) |
| Combined CNS/BM | 42 (1.9) | 16 (2.5) | 20 (1.5) | 6 (2.5) |
| Combined BM/local | 12 (0.6) | 1 (0.2) | 2 (0.2) | 9 (3.7) |
| Other combined | 28 (1.3) | 4 (0.6) | 16 (1.2) | 8 (3.3) |
| Second malignancy | 10 (0.5) | 2 (0.3) | 7 (0.5) | 1 (0.4) |
| Lost to follow-up | 24 | 7 | 17 | 0 |
| CCR | 1687 (77.5) | 545 (85.7) | 1058 (81.4) | 84 (34.6) |
| Result . | All patients, No. (%) (total n = 2178) . | Risk group, no. (%) of patients . | ||
|---|---|---|---|---|
| SRG (n = 636) . | MRG (n = 1299) . | HRG (n = 243) . | ||
| Death before remission3-150 | 22 (1.0) | 2 | 17 | 3 |
| Resistant disease | 16 (0.7) | 0 | 0 | 163-151 |
| CR achieved | 2140 (98.3) | 634 (99.7) | 1282 (98.7) | 224 (92.2) |
| Died in CR1 | 34 (1.6) | 5 | 16 | 13 |
| Relapses | ||||
| All | 385 (17.7) | 75 (11.8) | 184 (14.2) | 126 (51.9) |
| BM | 259 (11.9) | 44 (6.9) | 120 (9.2) | 95 (39.1) |
| CNS | 22 (1.0) | 7 (1.1) | 11 (0.8) | 4 (1.6) |
| Testes | 17 (0.8) | 3 (0.9) | 11 (1.5) | 3 (1.2) |
| Other isolated relapse | 5 (0.2) | — | 4 (0.4) | 1 (0.4) |
| Combined CNS/BM | 42 (1.9) | 16 (2.5) | 20 (1.5) | 6 (2.5) |
| Combined BM/local | 12 (0.6) | 1 (0.2) | 2 (0.2) | 9 (3.7) |
| Other combined | 28 (1.3) | 4 (0.6) | 16 (1.2) | 8 (3.3) |
| Second malignancy | 10 (0.5) | 2 (0.3) | 7 (0.5) | 1 (0.4) |
| Lost to follow-up | 24 | 7 | 17 | 0 |
| CCR | 1687 (77.5) | 545 (85.7) | 1058 (81.4) | 84 (34.6) |
CR indicates complete remission; CR1, first CR; BM, bone marrow; CNS, central nervous system; and CCR, complete clinical remission. Numbers in parenthesis are percentages calculated in relation to initial number of patients. Event-free survival (±SE) at 6 years was 78% ± 1% in all patients, 85% ± 2% in the SRG, 82% ± 1% in the MRG, and 34% ± 3% in the HRG.
Excluding patients with nonresponse.
Four patients initially met the criteria for the MRG by having a good response to prednisone.